Sponsor or institution
Clinical trials and research at Shandong New Time Pharmaceutical Co., LTD
As of November 12, 2026, Find a Trial lists 5 clinical trials run by Shandong New Time Pharmaceutical Co., LTD that are recruiting, in China. By phase: Phase 3 (2), Phase 2/3 (1), Phase 2 (1), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Targeting B cells and plasma cells in lupus with a dual-action antibody | Phase 1 | Shanghai | Recruiting | Sep 21, 2026 |
| F520 with paclitaxel and carboplatin as first-line therapy for cancer of unknown primary | Phase 2/3 | Shanghai, Shanghai Municipality | Recruiting | Aug 12, 2026 |
| F182112 versus standard care for relapsed or refractory multiple myeloma | Phase 3 | Tianjing | Recruiting | May 12, 2026 |
| F182112 given with other drugs for relapsed or refractory multiple myeloma | Phase 2 | Tianjin | Recruiting | Dec 31, 2025 |
| Cetirizine injection for treating acute urticaria | Phase 3 | Beijing, Beijing Municipality | Recruiting | Feb 11, 2025 |
All recruiting trials (5)
-
Targeting B cells and plasma cells in lupus with a dual-action antibody
A new injectable therapy (F182112) will be tested in adults with systemic lupus erythematosus to see if it can help by hitting both CD3 on immune cells and BCMA on B cells and plasma cells.
-
F520 with paclitaxel and carboplatin as first-line therapy for cancer of unknown primary
This trial tests whether adding F520 to standard chemotherapy can improve responses in adults with cancer of unknown primary who have not yet received systemic therapy.
-
F182112 versus standard care for relapsed or refractory multiple myeloma
This study will test whether F182112 works better than standard treatments for adults whose multiple myeloma has come back or stopped responding after prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
-
F182112 given with other drugs for relapsed or refractory multiple myeloma
This trial will test whether F182112, given with different drug regimens, helps people whose multiple myeloma has returned or stopped responding to prior treatments.
-
Cetirizine injection for treating acute urticaria
This study is testing if an injection of cetirizine can help adults with acute urticaria feel better and itch less compared to a standard treatment.
Quick answers
How many clinical trials run by Shandong New Time Pharmaceutical Co., LTD are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 2, Phase 2/3: 1, Phase 2: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.